These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32880833)

  • 21. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
    Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
    Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Campanini N; Azzoni C; Bordi C; Ardizzoni A;
    Br J Cancer; 2013 Apr; 108(8):1695-703. PubMed ID: 23549037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer.
    Bu L; Zhang LB; Mao X; Wang P
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
    Zhao X; Zhang Z; Yuan Y; Yuan X
    Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
    Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G
    PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
    Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
    Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
    Kalikaki A; Voutsina A; Koutsopoulos A; Papadaki C; Sfakianaki M; Yachnakis E; Xyrafas A; Kotsakis A; Agelaki S; Souglakos J; Mavroudis D; Georgoulias V
    Cancer Invest; 2015 Apr; 33(4):107-13. PubMed ID: 25647444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
    Han ZG; Tao J; Yu TT; Shan L
    Med Sci Monit; 2017 Apr; 23():1999-2006. PubMed ID: 28442702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
    Powrózek T; Mlak R; Krawczyk P; Homa I; Ciesielka M; Kozioł P; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Feb; 18(2):125-31. PubMed ID: 26193985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
    Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
    Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
    Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
    Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia.
    Abo-Bakr A; Mossallam G; El Azhary N; Hafez H; Badawy R
    J Egypt Natl Canc Inst; 2017 Sep; 29(3):127-133. PubMed ID: 28844589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
    Liu YP; Ling Y; Zhang YP; Liu BR
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.